Clonidine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Clonidine
- Pharmacist Assessment Report
- Clonidine: alpha-2 adrenergic agonist → faciodigitogenital syndrome
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Review Log
- Disclaimer
Clonidine: alpha-2 adrenergic agonist → faciodigitogenital syndrome
One-Sentence Summary
Clonidine is a centrally acting alpha-2 adrenergic agonist sold in India as oral tablets and an injection. The TxGNN model predicts it may be useful for faciodigitogenital syndrome, with a score of 0.9999. No clinical trials or publications currently support this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | faciodigitogenital syndrome |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (20 of 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | 20 (valid: 20) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Clonidine is known as an alpha-2 adrenergic agonist that lowers noradrenergic tone, but no data compiled for this report links that action to faciodigitogenital syndrome.
Faciodigitogenital syndrome is a rare developmental syndrome. No plausible alpha-2 adrenergic pathway is known in its pathogenesis. The very high score is therefore best read as a computational artifact rather than a mechanism-based signal. The prediction is not supported by any trial, publication or mechanistic argument.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Clonidine is marketed in India. All 20 records are valid. The data compiled for this report carry no approved-indication text for these records. The main ones are listed below.
Review correction (2026-11-06): Originally stated: “All 20 records are valid, and all are single-ingredient products.” Removed: the number or status of product records stated here did not match the Indian medicine data (the Indian Medicine Dataset as of 2026-11-06). The data list 20 product records for this drug, 20 current; the Quick Overview and the table under India Market Information show the current figures. Source: Indian Medicine Dataset.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 612 | Arkamin H Tablet | Strip of 10 tablets | Not recorded |
| 37962 | Cata-Dict 0.1 Tablet | Strip of 10 tablets | Not recorded |
| 36402 | Catapres 150mcg Tablet | Bottle of 100 tablets | Not recorded |
| 1751 | Arkapres 150 Tablet | Strip of 10 tablets | Not recorded |
| 34732 | Cloneon Injection | Vial of 1 ml injection | Not recorded |
Safety Considerations
- Drug Interactions: 234 interactions were identified. The ones listed here are all of moderate level. They include corticosteroids (hydrocortisone, triamcinolone, dexamethasone, betamethasone, budesonide), morphine, bupropion, dronabinol, SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin), sulfonylureas (chlorpropamide, acetohexamide, glimepiride, glipizide, glyburide) and insulins.
Please refer to the package insert for other safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The score is very high, but there are no clinical trials, no publications and no plausible mechanistic link. The prediction is likely a model artifact, and evidence is at the lowest level (L5).
To proceed, the following is needed:
- Mechanism of action data for clonidine and any biological rationale linking alpha-2 agonism to this syndrome
- Preclinical or case-level evidence in the condition
- Package insert warnings and contraindications for the Indian products
Review Log
Below is the review log for this page: statements checked against official Indian medicine data (the Indian Medicine Dataset used by this site). Corrections are limited to basic factual statements; model predictions, evidence levels, and conclusions were not rewritten.
| Review date | Item | Action | Source |
|---|---|---|---|
| 2026-11-06 | Removed: “and all are single-ingredient products” | Corrected | Indian Medicine Dataset |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.